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Abstract 
Pseudomyogenic hemangioendothelioma (PHE) is 
an intermediate malignant vascular tumor primarily 
affecting soft tissues in children and young adults. 
The molecular basis of this neoplasm is unknown. 
Chromosome banding analysis, fluorescence in situ 
hybridization (FISH), mRNA sequencing, RT-PCR, 
and quantitative real-time PCR have shown that 
PHEs are characterized by a balanced translocation 
t(7;19)(q22;q13), resulting in the fusion of the 
SERPINE1 and FOSB genes. The role of 
SERPINE1, which is highly expressed in vascular 
cells, in this gene fusion is probably to provide a 
strong promoter for FOSB. FOSB encodes a 
transcription factor belonging to the FOS family of 
proteins, which together with members of the JUN 
family of transcription factors are major 
components of the Activating Protein 1 (AP-1) 
complex. 
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Clinics and pathology 
Note 
Newly recognised entity. Rare. Exact incidence not 
known. 
Etiology 
Not known. 
Epidemiology 
Often young adults. Predominantly male (4.6:1) 
Clinics 
Two thirds of the lesions seen in limbs followed by 
trunk and head and neck. Size 0.3-5.5 cm. Often 
multifocal and ill circumscribed. Situated 
subcutanously but often in different tissue planes, 
including bone. Painful nodules in 50% of the 
cases. Locally aggressive and often recurring but 
rarely distant metastases. (Hornick et al., 2011) 
Pathology 
Spindle cells in fascicles and sheets. Vesicular 
nuclei. Distinct eosinophilic cytoplasm. Cells often 
show a rhabdomyoblast-like appearance. 
Treatment 
Surgical resection 
Genetics 
PHE consistently displays a SERPINE1-FOSB 
fusion gene, resulting from a translocation between 
chromosomes 7 and 19, presumably constituting the 
essential driver mutation in this neoplasm 
(Trombetta et al., 2011). 
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Interphase FISH with BAC probes showing normal red (SERPINE1) and green (FOSB) signals and yellow fusion (SERPINE1-
FOSB) signal. 
 
 
Chromatogram showing the fusion junction in a case of PHE. Sixty-one nucleotides from intron 1 of SERPINE1 were inserted at 
the fusion junction (blue double arrow). The translation start codon in FOSB is indicated (black arrow). 
 
 
Cytogenetics 
Cytogenetics Morphological 
a recurrent translocation t(7;19)(q22;q13) has been 
seen. 
Genes involved and 
proteins 
Note 
SERPINE1 and FOSB 
SERPINE1 
Location 
7q22.1; chr7:100,770,370-100,782,547 
DNA / RNA 
12,178 nt 
Protein 
SERPINE1 (aka PAI-1, plasminogen activator 
inhibitor type 1) encodes a protein that is a member 
of the serine protease inhibitor family, and that 
inhibits tissue- and urokinase-type plasminogen 
activators. These activators convert plasminogen to 
plasmin, which in turn mediates fibrinolysis and 
proteolytic degradation of extracellular matrix. It is 
highly expressed in many tumors, being implicated 
in invasion, angiogenesis and metastasis (Declerck 
et al., 2013). 
FOSB 
Location 
19q13.32; chr19:45,971,253-45,978,437 
DNA / RNA 
7,185 nt 
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Protein 
Member of FOS family of genes, which code for 
leucine zipper proteins that act as transcription 
factors. FOSB consists of 338 amino acids (aa), 
with a central basic leucine-zipper region and a 
carboxy-terminal transactivation domain (TAD) 
(Milde-Langosh, 2005). 
Result of the chromosomal 
anomaly 
Hybrid Gene 
Transcript 
RT-PCR and subsequent sequencing of amplified 
products from two cases identified an in-frame 
SERPINE-/FOSB fusion transcripts in both cases. 
In both tumors the breakpoints in SERPINE1 were 
located in the non-coding exon 1. The breakpoint in 
FOSB was located in the beginning of exon 2 in 
one case and in the non-coding exon 1 in the other. 
Both cases showed small insertions (61 bp in Case 
1, 59 bp in Case 2) of material from intron 1 of 
SERPINE1 at the fusion junction (Walther et al., 
2014). 
Fusion Protein 
Oncogenesis 
The role of SERPINE1 in the SERPINE1-FOSB  
chimera is probably to provide a promoter allowing 
strong expression of FOSB. 
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